SOPH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
SOPHiA GENETICS SA is not a strong buy at the moment for a beginner, long-term investor. While the company shows promising revenue growth and strategic partnerships, the technical indicators are neutral, and the financials still reflect losses. Additionally, there are no strong trading signals or significant positive catalysts to justify immediate action.
The MACD is below zero and negatively contracting, indicating a bearish trend. RSI is neutral at 43.336, and moving averages are converging, suggesting no clear direction. The stock is trading near its pivot level of 4.444, with support at 4.11 and resistance at 4.778.
The company reported a 22% YoY revenue increase in Q4 2025 and a full-year growth of 19%. It also signed 124 new customers and partnered with two major U.S. health systems, which could drive future growth. Hedge funds have significantly increased their buying activity, up 1033.12% over the last quarter.
Gross margin dropped slightly YoY, and the net income remains negative at -$19.18 million. Technical indicators do not suggest a strong upward trend, and there are no significant insider or congress trading activities.
In Q4 2025, revenue increased by 22.41% YoY to $21.7 million. Net income improved by 26.53% YoY but remains negative at -$19.18 million. EPS improved by 21.74% YoY to -$0.28. Gross margin decreased slightly to 67.68%, down -0.84% YoY.
Guggenheim recently raised the price target from $6 to $7 and maintained a Buy rating, reflecting confidence in the company's growth potential.
